Megestrol acetate
Megestrol (megestrol acetate) is a small molecule pharmaceutical. Megestrol acetate was first approved as Megace on 1982-01-01. It is used to treat anorexia, breast neoplasms, cachexia, and endometrial neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Megestrol (discontinued: Megace, Megestrol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Megestrol acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MEGACE | Bristol Myers Squibb | N-020264 DISCN | 1993-09-10 | 1 products, RLD |
| MEGACE | Bristol Myers Squibb | N-016979 DISCN | 1982-01-01 | 2 products, RLD |
| MEGACE ES | Endo | N-021778 DISCN | 2005-07-05 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| megace es | New Drug Application | 2014-03-18 |
| megestol | ANDA | 2010-01-22 |
| megestrol acetate | ANDA | 2025-05-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
| endometrial neoplasms | EFO_0004230 | D016889 | — |
| cachexia | — | D002100 | R64 |
| anorexia | — | D000855 | R63.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03A: Hormonal contraceptives for systemic use
— G03AA: Progestogens and estrogen systemic contraceptives, fixed combinations
— G03AA04: Megestrol and ethinylestradiol
— G03AB: Progestogens and estrogens systemic contraceptives, sequential preparations
— G03AB01: Megestrol and ethinylestradiol
— G03AC: Progestogen systemic hormonal contraceptives
— G03AC05: Megestrol
— G03D: Progestogen sex hormones and modulators of the genital system
— G03DB: Pregnadien derivatives, progestogens
— G03DB02: Megestrol
— G03F: Progestogens and estrogens in combination
— G03FA: Progestogens and estrogens, fixed combinations
— G03FA08: Megestrol and estrogen
— G03FB: Progestogens and estrogens, sequential preparations
— G03FB04: Megestrol and estrogen
L: Antineoplastic and immunomodulating agents
— L02: Endocrine therapy antineoplastic and immunomodulating agents
— L02A: Hormones and related agents
— L02AB: Progestogens, endocrine therapy drugs
— L02AB01: Megestrol
HCPCS
Code | Description |
|---|---|
| S0179 | Megestrol acetate, oral, 20 mg |
Clinical
Clinical Trials
105 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cachexia | D002100 | — | R64 | 2 | 10 | 9 | 3 | 2 | 25 |
| Wasting syndrome | D019282 | — | — | 1 | 9 | 9 | 1 | 2 | 21 |
| Anorexia | D000855 | — | R63.0 | 1 | 8 | 8 | 2 | — | 18 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 3 | 1 | 1 | 2 | 8 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | 1 | 1 | — | 2 |
| Second primary neoplasms | D016609 | — | — | — | — | — | 1 | — | 1 |
| Feeding and eating disorders | D001068 | — | F50 | — | — | — | 1 | — | 1 |
| Feeding behavior | D005247 | — | — | — | — | — | 1 | — | 1 |
| Feeding and eating disorders of childhood | D019959 | — | — | — | — | — | 1 | — | 1 |
| Precocious puberty | D011629 | — | E22.8 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 4 | 18 | 4 | — | 3 | 24 |
| Neoplasms | D009369 | — | C80 | — | 9 | 5 | — | 2 | 15 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | 13 | 7 | — | 1 | 15 |
| Endometrial hyperplasia | D004714 | — | N85.0 | — | 12 | 7 | — | 1 | 14 |
| Carcinoma | D002277 | — | C80.0 | — | 7 | 4 | — | 1 | 11 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 5 | 2 | — | — | 7 |
| Weight loss | D015431 | — | — | — | 4 | 4 | — | — | 7 |
| Endometrioid carcinoma | D018269 | — | — | 1 | 4 | 1 | — | 2 | 6 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | 4 | — | — | 5 |
| Infertility | D007246 | EFO_0000545 | — | — | 4 | 3 | — | — | 4 |
Show 24 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | 4 | — | — | 1 | 6 |
| Hiv wasting syndrome | D019247 | EFO_0007312 | — | 1 | 2 | — | — | 1 | 4 |
| Recurrence | D012008 | — | — | 1 | 3 | — | — | — | 3 |
| Carcinoma in situ | D002278 | — | D09.9 | — | 2 | — | — | — | 2 |
| Uterine neoplasms | D014594 | EFO_0003859 | C55 | — | 2 | — | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | 1 | 2 | — | — | — | 2 |
| Fatigue | D005221 | — | R53.83 | — | 1 | — | — | 1 | 2 |
| Vomiting | D014839 | — | R11.1 | — | 1 | — | — | — | 1 |
| Nausea | D009325 | — | R11.0 | — | 1 | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | — | 1 |
Show 18 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | 1 | 3 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Absorption | D000042 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 3 | 3 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 2 | 2 |
| Adrenal insufficiency | D000309 | — | — | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | — | — | — | — | 1 | 1 |
| Failure to thrive | D005183 | — | — | — | — | — | — | 1 | 1 |
| Fertility preservation | D059247 | — | — | — | — | — | — | 1 | 1 |
| Digestive system neoplasms | D004067 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Megestrol acetate |
| INN | megestrol |
| Description | Megestrol acetate is a steroid ester resulting from the formal condensation of the hydroxy group of megestrol with the carboxy group of acetic acid. It is an appetite stimulant used for the treatment of anorexia and cachexia. Also used for birth control and for the treatment of breast cancer. It has a role as an antineoplastic agent, an appetite enhancer, a contraceptive drug, a progestin and a synthetic oral contraceptive. It is a steroid ester, an acetate ester, a 20-oxo steroid and a 3-oxo-Delta(4) steroid. It is functionally related to a megestrol. |
| Classification | Small molecule |
| Drug class | estrogens; progestins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 595-33-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201139 |
| ChEBI ID | — |
| PubChem CID | 11683 |
| DrugBank | DB00351 |
| UNII ID | EA6LD1M70M (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Megestrol acetate
+
Megestrol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,272 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use